Ardelyx's Commitment to Investor Engagement
WALTHAM, Mass. — Ardelyx, Inc. (Nasdaq: ARDX), a pioneering biopharmaceutical company, is excited to announce its engagement in several impactful investor conferences. Founded to innovate and commercialize first-in-class medicines, Ardelyx is dedicated to addressing critical unmet medical needs. Through these events, the company aims to connect with investors and share its future developments.
Upcoming Conferences and Presentation Details
Ardelyx will participate in the following events, enabling stakeholders to gain insights into the company’s progress and future initiatives:
Leerink Partners 2025 Global Healthcare Conference
This prominent conference is set to take place in Miami, FL. Ardelyx is scheduled to present on Tuesday, March 11 at 8:00 a.m. ET, followed by one-on-one meetings that same day. Attendees can learn about the company's innovative approaches during this session.
Jefferies Biotech on the Beach Summit
Also in Miami, FL, Ardelyx will host one-on-one meetings on Wednesday, March 12. This summit represents another valuable opportunity for investors to engage with Ardelyx representatives and discuss the company’s innovative product pipeline.
Barclays Annual Global Healthcare Conference
Following the previous events, Ardelyx will take the stage at the Barclays 27th Annual Global Healthcare Conference in Miami, FL. The company’s fireside chat is scheduled for Thursday, March 13 at 10:00 a.m. ET, with additional one-on-one meetings available that day as well. The chat will delve into advancements in Ardelyx's strategies and recent successes.
Investors and interested parties can access the live webcasts of the presentations through the Events and Presentations section on the Ardelyx website. Replays will be available for 30 days following each event, ensuring those who may miss the live sessions can stay informed.
About Ardelyx, Inc.
Ardelyx has emerged as a leader in the biopharmaceutical space, delivering innovative solutions to address significant health challenges. The company boasts two approved commercial products in the U.S.: IBSRELA (tenapanor) and XPHOZAH (tenapanor). Additionally, Ardelyx collaborates with Kyowa Kirin to commercialize PHOZEVEL (tenapanor) for managing hyperphosphatemia in Japan. Furthermore, the company has submitted a New Drug Application for tenapanor regarding hyperphosphatemia in China in collaboration with Fosun Pharma.
Ardelyx is also partnered with Knight Therapeutics to commercialize IBSRELA in Canada. This robust network of partnerships showcases Ardelyx's commitment to extending its innovative solutions globally.
Investor and Media Contacts
For more information, inquiries can be directed to Caitlin Lowie at Ardelyx. She can be reached via email for any additional questions concerning the company's presentation schedule or product information.
Frequently Asked Questions
What is Ardelyx's mission?
Ardelyx aims to discover and commercialize innovative first-in-class medicines to meet critical unmet medical needs.
Which conferences is Ardelyx participating in?
Ardelyx will participate in the Leerink Partners Global Healthcare Conference, Jefferies Biotech on the Beach Summit, and Barclays Annual Global Healthcare Conference.
Where can I access Ardelyx's conference presentations?
The live webcasts of the presentations will be available on the Ardelyx website, with replays accessible for 30 days post-event.
What products has Ardelyx commercialized?
Ardelyx has commercialized IBSRELA and XPHOZAH in the U.S. and has various partnerships for its products in international markets.
Who can I contact for more information about Ardelyx?
For further inquiries, Caitlin Lowie at Ardelyx can be contacted for detailed information regarding presentations and products.
